Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics Orion Corporation (“Orion”) and Invenra Inc. (“Invenra”), an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body® platform. Under the te ...